ERCC2 [Xeroderma pigmentosum (XP) group D] belongs to the nucleotide excision repair pathway. It is also part of the TFIIH transcription complex and is required for the association of the cyclin-dependent kinase (CDK)-activating kinase (CAK) subcomplex with TFIIH. Using the NCI-60 panel of human tumor cell lines, we had shown that the ERCC2 gene variant Gln 751 was significantly associated to increased taxanes sensitivity and decreased ERCC2 gene expression. Since TFIIH is involved in both DNA repair and cell cycle progression, we hypothesized that quantitative or qualitative ERCC2 alterations might cause CAK liberation, allowing its activation of the G 2 /M transition. Enhancing mitosis entry would lead to hypersensitivity to spindle poisons, explaining the effect of ERCC2 polymorphisms on taxane sensitivity. Starting from ERCC2-deficient XP6BE, we generated several isogenic clones differing only by the Lys751Gln variation. Wild-type and variant ERCC2-expressing clones recovered ultraviolet radiation and cisplatin resistance but presented similar sensitivity to paclitaxel, demonstrating that the amino acid change was not involved in paclitaxel differential sensitivity in the NCI-60 panel. Using small interfering RNA approach, we knocked down ERCC2 expression and observed a block in the G 2 /M phase, with a consistent increase in paclitaxel sensitivity and no change in cisplatin sensitivity. We observed in addition an increase in CDK1 activity, as evaluated by histone H1 phosphorylation. We evaluated messenger RNA (mRNA) half-life in the isogenic lines and observed a more rapid degradation in cells bearing the variant construct. We concluded that the increased paclitaxel sensitivity of ERCC2 variant cell lines is a consequence of lower gene expression, likely due to decreased stability of the variant ERCC2 mRNA.
Introduction
The individualization of cancer chemotherapy has become a challenge in recent years. The oncologist now has a wide armamentarium of classical and targeted drugs from which to select the most appropriate ones for the treatment of a unique patient. Controlled clinical trials are required for the demonstration that a drug is efficient toward a defined cancer; they should also be required for the demonstration that a drug should be rather prescribed in a particular subset of patients. Few achievements have yet been made in that direction and anticancer drugs remain prescribed similarly in large patients' cohorts without taking into account either the molecular characteristics of the tumor or the genetics of the patient. The restriction of cetuximab prescription to the patients whose colorectal tumor presents an activating KRAS mutation (1) and the restricted use of trastuzumab to breast cancer patients with a tumor amplification of ERBB2 (2) are the best known recent examples which were added to estrogen receptor-based tamoxifen prescription. There are presently no such opportunities for the prescription of classical cytotoxic agents despite the tremendous amount of work that has been performed in order to identify molecular predictors of drug activity.
Discovering new predictors of drug efficacy or toxicity which could be used in the clinical setting is generally based upon mechanistic considerations: researchers first look at molecular alterations in the pathways involved in the transport, metabolism and elimination of the drug or at the level of its identified primary targets. The role of topoisomerase II expression in anthracycline activity (3) or that of the microtubule-associated Tau protein in paclitaxel activity (4) have been recently explored and proposed as clinically useful parameters for prescription guidance. Another approach consists of naive explorations of the relationships between drug activity and molecular features in preclinical models; the discovery of such associations should then be validated both at the mechanistic and at the clinical levels. We have implemented such investigations using the panel of 60 human tumor cell lines of the National Cancer Institute (NCI-60) as a model and identified several unexpected correlations. Especially, we observed with this model that a highly significant relationship existed between the presence of a common polymorphism of a gene involved in the DNA nucleotide excision repair (NER) pathway, Excision repair cross-complementation group 2 (ERCC2), also called Xeroderma pigmentosum (XP) group D and cell sensitivity to a variety of anticancer drugs, especially spindle poisons (5) .
An association between a polymorphism of a NER gene and the activity of alkylating agents would be rationally explained since the lesions caused by these agents are commonly repaired by NER (6) . However, such an association was unexpected for spindle poisons because there is no obvious relationship between their mechanism of action and DNA repair. We decided thus to explore this relationship and try to decipher its mechanistic origin, starting from the hypothesis that there was a link between the ERCC2 protein and mitosis. It has been shown recently that ERCC2 was involved in cell cycle regulation because of its association to the ctyclin-dependent kinase (CDK)-activating kinase (CAK) complex (CDK7-cyclin H-MAT1), which is involved in transcription as member of the TFIIH complex and which regulates cell cycle entry through phosphorylation and activation of CDK1 (7) . CDK1 is the catalytic component of the maturationpromoting factor, which triggers mitosis and is involved in most mitotic events. The restricted availability of CAK for either transcription, DNA repair or mitosis entry is a crucial feature, which compels cell to maintain its integrity before dividing. We hypothesized that qualitative or quantitative alterations of the ERCC2 protein, which actively recruits the CDK7 complex to the TFIIH core (7), could be involved in CAK availability for mitosis entry and, therefore, for taxane sensitivity (8) . The present work aims at exploring the validity of this hypothesis to explain the unexpected relationship between ERCC2 polymorphism and taxane sensitivity.
Deleterious mutations of the ERCC2 gene are characterized, among other features, by ultraviolet (UV) hypersensitivity and skin cancer predisposition in XP or tricholeucodystrophy and XP-Cockayne syndrome patients (9) . Polymorphisms in this gene have been the subject of intense work aimed at finding whether they had functional consequences and could be associated to altered cancer susceptibility. Epidemiologic studies raised conflicting results concerning the common Lys751Gln variation (rs13181) of ERCC2, but a recent meta-analysis of 56 case-control studies (10) concluded that the variant Gln 751 allele was associated with a slight but significant increase of cancer risk, especially for esophageal carcinoma and acute lymphoblastic leukemia. This was not the case for the other common Asp312Asn variation (rs1799793). At the molecular level, the wild-type ERCC2 Lys 751 and the variant ERCC2 Gln 751 proteins were isolated and tested for capacity in DNA repair in a reconstituted TFIIH system; no difference was exhibited between the functional ability of these proteins (11) . However, it was suggested, on the basis of messenger RNA (mRNA) secondary structure, that the mRNA encoding the variant Gln 751 ERCC2 protein was less stable than the wild-type mRNA encoding the Lys 751 protein, whereas no difference was exhibited by the mRNA encoding the two ERCC2 isoforms differing at the level of amino acid #312 (12) . Furthermore, high protein levels were shown to correlate with anticancer drug resistance (including alkylating agents and taxanes) in human tumor cell lines (13) . More recently, high levels of ERCC2 mRNA expression were associated with drug resistance in ovarian cancer patients (14) . In order to analyze the effects of the polymorphic variation of ERCC2, we generated cellular variants expressing the two polymorphic forms of this protein and evaluated their UV, cisplatin and paclitaxel sensitivity. In addition, considering that the ERCC2 Lys751Gln polymorphism could be associated with a reduction of protein availability, we performed small interfering RNA (siRNA) extinction of the protein for testing cisplatin and paclitaxel sensitivity on cellular models. In addition to the classical role of ERCC2 in transcription and DNA repair, our results are in favor of a role of this protein in triggering mitosis and sensitizing cells to the action of spindle poisons.
Materials and methods

Cells and cell culture
We have used the SV-40 immortalized skin fibroblast line established from a 19-year-old female with XP, complementation group D, the XP6BE line supplied by the Coriell Institute (Camden, NJ). This line expresses a truncated protein originating from one allele and a protein with a single-site mutation (Arg683Trp) originating from the other one, none of the proteins being functional (15) .
Cells were grown in standard Dulbecco's modified Eagle's medium (Invitrogen, Cergy-Pontoise, France) in the presence of 10% fetal calf serum (Pan Biotech) in petri dishes or flasks of various sizes. They were maintained at 37°C in a humidified atmosphere containing 5% CO 2 . They were replicated every 4 days and the medium changed once in between.
For cytotoxicity evaluations, cells in exponential growth were trypsinized and resuspended in fresh culture medium to give a concentration of 10 3 cells per 200 ll. The cell suspensions were seeded into 96-well plates and incubated for 48 h at 37°C. After incubation, the medium was replaced with fresh culture medium supplemented by drugs at appropriate concentrations. After 72 h incubation at 37°C, cell survival was estimated after 3-(4,5-dimethylthiazole-2-yl)-2,5-bdiphenyl tetrazolium bromide coloration at 570 nm.
Cloning and transfection
We first cloned the complementary DNA (cDNA) of the ERCC2 gene originating from a human mRNA collection in a pcDNA3.1 plasmid using the Topo/ TA cloning method and a HisV5 tag for labeling the gene (Invitrogen). This plasmid contains an SV-40 origin of replication allowing an episomic replication of the vector in eukaryotic cells expressing the T antigen of SV-40. Since this was not suitable for stable transfections, we subcloned the cDNA in a plasmidic vector not containing an SV-40 origin of replication, pTRACER, and containing a blasticidin-resistance gene labeled with a green fluorescent protein tag. Plasmidic DNA was isolated from bacterial cultures with the HiSpeed Plasmid mini or midikit (Qiagen).
After subcloning of the cDNA of the wild-type alleles of ERCC2, the variant allele was obtained by site-directed mutagenesis using a kit purchased from Stratagene (Agilent, Massy, France). A set of 40mer primers was designed with the variant nucleotide in the middle. PCR was carried out as recommended by the manufacturer, using durations of 1 min/kilobase. PCR products were digested with DpnI and used for transformation of the competent bacteria. A positive control for mutagenesis was carried out in parallel, using the complementation of a non-mutated form of b-galactosidase. The genotypes obtained before and after mutagenesis were controlled by restriction fragment length polymorphism followed by sequencing of the ligation sites of the PCR products. The complete cDNA were then sequenced by Cogenics (Grenoble, France)
Transfection was performed on the defective cell line XP6BE with the appropriate plasmids. Transfection was done in the presence of lipofectamine 2000 (Invitrogen) using as an external control the LacZ gene instead of the gene of interest. Selection was performed using 5 lg/ml of blasticidin for 2 weeks after determination of the optimal concentration of the antibiotic. Transfected cells were submitted to flow cytometry in order to determine the proportion of cells expressing green fluorescent protein and to sort out the fluorescent cells. The cells having integrated the plasmid were then amplified for several weeks and submitted to a second run of flow cytometry and sorting out to verify plasmid integration; thereafter, the cells were cloned and clonality was checked by flow cytometry.
Transgene integration was verified by PCR and the presence of the right molecular variant checked by pyrosequencing. Transgene mRNA expression was then verified by quantitative real-time reverse transcription-PCR (RT-PCR) and the clones expressing the molecular variants of the transgenes at the same level were selected for further studies. ERCC2 protein expression was evaluated by western blotting to ensure that the protein was expressed at the expected molecular weight.
RNA isolation and RT-PCR
Total RNA was isolated using the RNeasy kit (Qiagen) and its concentration determined by spectrometry. Quality and integrity of total RNA was assessed using the Bioanalyzer (Agilent). For the cloning, first-strand cDNA was synthesized using 1 lg of total RNA (DNase-treated) in a 20 ll reverse transcriptase reaction containing 200 U Superscript III (Invitrogen) and 0.5 lg oligodeoxythymidine primer. For real-time RT-PCR, the reverse transcriptase reaction was carried out with 500 ng total RNA in a 20 ll mixture to generate first-strand cDNA using the Superscript VILO cDNA synthesis kit (Invitrogen). All real-time PCR reactions were performed in a 20 ll mixture containing 1/10 volume of cDNA preparation using Express SYBR GreenER qPCR SuperMixes and Two-Step quantitative RT-PCR kits (Invitrogen) according to manufacturer's protocol. Real-time quantifications were performed using the Rotor-Gene 3000 (Corbett Life Sciences). The fluorescence threshold value was calculated using Rotor-Gene 5 software (Corbett Life Sciences).
Protein extraction and western blotting
Cell pellets were solubilized in 1 ml phosphate-buffered saline (PBS) at þ4°C. Lysates were centrifuged for 5 min at 3000g. Pellets were resuspended in a lysis buffer RIPA [Tris-HCl, pH 8, 50 mM; NaCl 150 mM; sodium dodecyl sulfate 0.1%; NP40 1%; sodium deoxycholate 0.5%; protease inhibitors cocktail 1Â (Roche)]. After 30 min on ice, the samples were centrifuged for 15 min at 15 000g. The supernatants containing soluble proteins were analyzed by western blotting: Fifty micrograms of proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto Immobilon-polyvinylidene difluoride membranes (Millipore), using a semidry transfer with a Milliblot Graphite Electroblotter (Millipore). Membranes were then blocked for 1 h in 5% skim milk in Tris-buffered saline-T (Tris-HCl, pH 7.5, 100 mM, NaCl 0.9%, Tween-20 0.05%) and incubated overnight at 4°C with primary antibody (Table I) diluted at the appropriate concentration in blocking solution. Blots were washed three times in Tris-buffered saline-T, and then incubated for 1 h with peroxidase-conjugated secondary antibody (Table I) . After washes, signals were detected using Enhanced chemiluminescenceþ reagent (GE Healthcare).
UV irradiation
A total of 10 6 cells were plated on 80 cm 2 petri dishes. After overnight incubation at 37°C, the cell culture medium was removed and replaced by PBS 1Â. Cells were then irradiated with increasing doses (0.4-4 J/m 2 ) of UVC (254 nm) using a UV light (Fisher Bioblock) . After UV irradiation, fresh growth medium was added and cells were grown for 3 days. At 72 h post-irradiation, the adherent cells were trypsinized and counted in triplicate with a Beckman Z2 counter.
Silencing ERCC2 with siRNA The XP6BE cells were seeded at 30% confluence in six-well plates and were transfected by a mixture of two different targeted siRNAs (Invitrogen) or by two different non-targeting siRNA for control. For each well, 25 ll of siRNA ERCC2 gene polymorphism and paclitaxel sensitivity was mixed with 500 ll Opti-Mem I. The mixture was then combined with a solution of 5 ll lipofectamine RNAiMax (Invitrogen); after 20 minute incubation at room temperature, the mixture was applied to the cells in a final volume of 2 ml of Dulbecco's modified Eagle's medium at a concentration of 100 nM for each siRNA. The sequences of the ERCC2-targeting siRNAs were the following ones: GCUUCGAAAGUUGCUCAACUUCUAU and GGUGCC-CAUACUUCCUUGCUCGAUA. After 48 h, the medium was changed and paclitaxel and cisplatin cytotoxicities were evaluated. The silencing of ERCC2 protein expression was verified by western blotting as already described.
Cell cycle distribution
Cell cycle distribution of XP6BE cells transfected with non-targeting or XP group D-targeting siRNA was studied by DNA content by fluorescence-activated cells sorting and analyzed using the Cell Quest Pro software (BD Biosciences).
Forty-eight and 56 h after transfection, cells were trypsinized, centrifuged at 1500g for 5 min and washed twice with PBS. They were then fixed with 70% ethanol at 4°C overnight and centrifuged at 1500g for 5 min. Ethanol was removed and cells washed twice with PBS. Three hundred microliters of a propidium iodide Ribonuclease-containing solution were added to the cells, which were then subjected to cell cycle analysis by fluorescence-activated cells sorting. The results of each assay are expressed in terms of percentage of cells in a given phase of the cycle. The data presented reflect four independent experiments performed. ERCC2 extinction was always monitored by western blotting.
Evaluation of CDK1 activity CDK1 activity was evaluated following the recommendations of Chabalier et al. (16) . At various times after 5 nM paclitaxel treatment, the siRNA-transfected cells were harvested and lysed. Seven hundred micrograms of protein extract in lysis buffer (Tris, pH 7.5 50 mM, NaCl 150 mM, ethylenediaminetetraacetic acid 5 mM, Triton X-100 0.25%, NaF 50 mM, Na 3 VO 4 1 mM, phenylmethylsulfonyl fluoride 100 lg/ml, dithiothreitol 1 mM and protease inhibitor cocktail) were diluted with binding buffer-containing protein A Mag sepharose Xtra beads (GE Healthcare); the mixture was incubated for 1 h on a benchtop shaker. After preclearing the complexes protein beads were washed two times in washing buffer and the purified proteins were eluted with elution buffer. The elution fraction was incubated with 5 lg of anti-CDK1 antibody overnight at 4°C. Antigen/antibody complexes were isolated with protein A Mag sepharose Xtra beads after 2 h of incubation and the purified proteins were eluted with 100 ll elution buffer. These purified proteins were incubated with 100 lM adenosine triphosphate (Pharmacia), 5 lCi of [ 32 P]ATP (Amersham Biosciences, GE) and 2.5 lg of histone H1 protein (Upstate, Millipore) for 10 min at 37°C. The reaction was stopped by addition of Laemmli buffer 4Â in 5 min at 95°C. Proteins were separated by electrophoresis on 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis, the radioactivity associated with H1 histone was quantified on a phosphorimager (Molecular Dynamics).
RNA structure modeling
We used the RNAfold software (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold. cgi) to design the secondary structure of wild-type and variants of ERCC2 mRNA. This software calculates also a theoretical free enthalpy value of the structures proposed.
ERCC2 mRNA stability assay Cells were seeded in six-well plates at 3.10 5 cells per well. After 48 h at 37°C, the transcriptional inhibitor actinomycin D (Invitrogen) was added at the final concentration of 5 lg/ml. Cells were recovered after 0, 9, 16 and 24 h and cell lysates were stored at À80°C. RNA extraction was performed and mRNA levels were evaluated by real-time RT-PCR with appropriate primers for ERCC2 and RNA 18S (Ambion Universal 18S primer pair). RT-PCR has already been described above. We used for ERCC2 a sequence of pTRACER3#untranslated region as the antisense primer in order to evaluate only the half-lives of the exogenous mRNA.
Results
The cytotoxicity of anticancer drugs toward the NCI panel as well as the expression of the ERCC2 gene were extracted from the NCI DTP database (5). In the NCI panel, the paclitaxel mean growth inhibitory concentration 50 value in homozygous ERCC2 Gln 751 cell lines was 4.7-fold lower than in homozygous Lys 751 cells (P 5 0.018) ( Figure 1A) . Considering the 13 different taxanes as a whole, the significance of the difference reached P 5 5.1 Â 10 À7 . The mRNA expression of the ERCC2 gene was 60% lower in homozygous ERCC2 Gln 751 cells than in homozygous Lys 751 cells (P 5 5.5 Â 10 À3 ) ( Figure 1B ). This decrease in mRNA matched indeed with a decrease in protein expression, as had been stated by Xu et al. (13) .
Considering that the association between ERCC2 genotype and taxane sensitivity could be linked to the Lys to Gln amino acid change in the corresponding protein, we aimed at generating isogenic cell lines expressing the two proteins at similar levels. Cloning of ERCC2 cDNAs in pcDNA3.1-V5, subcloning of ERCC2-V5 cDNA in pTRACER and site-directed mutagenesis were performed as described in Material and methods. Sequencing of the complete cDNAs showed that these steps did not provide alterations in cDNA sequence, with the exception of one clone which was discarded. Transfection of this construction was done into immortalized XP6BE cells and transfection rate was $30%, as estimated from the parallel transfection of the LacZ gene in the cell line and coloration with X-gal. Several clones were selected for their expression of the wildtype (Lys 751 ) and the variant (Gln 751 ) constructs of the V5-tagged ERCC2 protein and three of each type were studied further: DWH5, DWH7 and DWH10 for the wild-type cDNA-harboring construct and DVA4, DVC1 and DVD6 for the variant cDNA-harboring construct. All clones expressed equivalent amounts of the V5-tagged ERCC2 (exogenous) protein as evidenced by western blotting with the anti-V5 antibody ( Figure 2A ) and by quantitative real-time RT-PCR (data not shown). No V5-tagged ERCC2 was detected in the control PBA9 clone transfected with the empty vector. Using an anti-ERCC2 antibody showed an important protein expression in all transfected clones, giving a signal 2-to 4-fold higher than that of the endogenous (mutated) protein observed in XP6BE or PBA9 cells ( Figure 2B ). UV-induced sensitivity was then evaluated in two representative clones, DWH10 and DVA4, as well as in the control PBA9 clone. Figure 3A shows that expression of similar levels of wild-type and variant V5-tagged ERCC2 proteins conferred the same level of resistance to UV when compared with the sensitive PBA9 control clone; this demonstrates that both forms of ERCC2 protein are functionally active in terms of DNA repair. Paclitaxel and cisplatin cytotoxicities were then evaluated on all the selected clones. Cisplatin appeared significantly more cytotoxic toward XP6BE and PBA9 cells than toward cells transfected with both ERCC2-V5 constructs ( Figure 3B) , showing that wildtype cDNA-and variant cDNA-transfected cells had similarly recovered functional DNA repair. No significant difference in paclitaxel cytotoxicity could be evidenced between clones transfected with the empty vector, the wild-type and the variant ERCC2-V5 cDNA ( Figure 3C ). These results show that the single-nucleotide polymorphism status of the ERCC2 protein at amino acid 751 does not influence the repair efficiency of cisplatin-or UV-induced DNA damage and cannot account for the difference in taxane sensitivity observed between the wild-type and the variant cell lines.
We then tested whether the association between ERCC2 Lys751Gln polymorphism and paclitaxel sensitivity in the NCI panel could originate from a change in ERCC2 expression levels in the variant cell lines. It is possible that reduced expression of ERCC2 could lead to reduced CAK activity and entry in mitosis, which could affect the activity of spindle poisons. Therefore, we downregulated the expression of the endogenous form of ERCC2 in XP6BE cells through siRNA transfection and evaluated its consequences on paclitaxel sensitivity. siRNAinduced downregulation of endogenous ERCC2 in XP6BE cells was of $70% at 72 h in the conditions described in Materials and methods. As shown in Figure 4A , XP6BE cells transfected with a siRNA directed against ERCC2 reproducibly showed higher sensitivity to paclitaxel as compared with cells transfected with a non-targeting siRNA. This confirms that cellular sensitivity to paclitaxel is linked to the level of ERCC2 protein rather than to its DNA repair function as endogenous XP6BE ERCC2 is inactive for its helicase activity. It is also in agreement with the results of Figure 1B showing a correlation between ERCC2 expression (associated to the Lys751Gln polymorphism) and paclitaxel sensitivity in the cell line panel of the NCI. It is also confirmed by the fact that downregulation of ERCC2 had no effect on XP6BE cell sensitivity to cisplatin ( Figure 4B ).
We analyzed cell cycle distribution of XP6BE cells after ERCC2 extinction. This was carried out at 48 and 56 h after siRNA transfection with a non-targeting or an ERCC2-targeting siRNA. As shown in Figure 5 , there was an increased proportion of cells in the G 2 /M phase, from 20 to 35%, when ERCC2 was downregulated. Simultaneous incubation with 2 or 5 nM paclitaxel did not modify these proportions (data not shown).
Since there was a block in G 2 /M phase upon ERCC2 silencing, we also tested whether the absence or presence of an active ERCC2 protein could affect cell mitosis entry via a mechanism involving CAK activity. We thus evaluated the link between endogenous ERCC2 levels of XP6BE cells on CDK1 activity through histone H1 phosphorylation as well as cyclin B1, CDK1 and CDK7 protein levels by western blotting, following treatment with low concentrations of paclitaxel to block the cells in G 2 /M and enhance CDK1 kinase activity ( Figure 6 ). We found that ERCC2 repression through specific siRNA transfection was followed by an increase in CDK1 activity and cyclin B1 levels as compared with control cells transfected with non-targeting siRNA, without changes in CDK1 or CDK7 concentrations, indicating a successful enhancement of cell entry into mitosis. These results strongly suggest that the level of ERCC2 expression is associated with mitosis entry and taxane sensitivity.
To explore the potential link between the ERCC2 Lys751Gln polymorphism status and the level of ERCC2 gene and protein expression, we evaluated ERCC2 mRNA secondary structure and stability. Using the RNAfold software, it appeared that the single nucleotide replacement at the 3# end of the mRNA generates a major alteration of the predicted secondary structure ( Figure 7A and B) . In contrast, the change at codon 312 induces did not predict any major change of the secondary structures of ERCC2 mRNA. Interestingly, we found that there was a significant difference in the half-lives of the mRNAs extracted from two wild-type and variant representative clones, DWH7 (5.7 h) and the DVA4 (4.4 h) ( Figure 7C ), suggesting that the difference in secondary structures of ERCC2 mRNA could account for the difference observed in the corresponding protein levels ( Figure 7D ).
Discussion
The work described here was aimed at understanding the associations we observed between a common polymorphism in the ERCC2 gene and tumor cell sensitivity to a variety of anticancer drugs in the NCI panel of 60 human tumor cell lines. The first hypothesis is that the amino acid change in a protein involved in NER leads to a reduction of its activity and, therefore, to an increased sensitivity to DNA-damaging agents. In order to study this hypothesis, we generated two isogenic cell lines containing a basically inactive protein and transfected with either polymorphic variants of a functional protein. Such cell lines, differing only by an amino acid substitution on the protein of interest, constitute an ideal model for exploring the functionality of gene polymorphisms.
It has been already reported in a cell-free system (11) that the ERCC2 Lys751Gln polymorphism had no measurable effect on NER. Our results are in agreement with this statement since no difference in cisplatin cytotoxicity was exhibited by XP6BE cells ERCC2 gene polymorphism and paclitaxel sensitivity transfected with the wild-type allele or with the variant allele of ERCC2, both cell lines expressing the transgene at a comparable level. However, this explanation cannot stand for the important increase in sensitivity to spindle poisons exhibited by the cell lines of the NCI panel harboring the variant allele at the homozygous state, as compared with those harboring no variant allele because spindle poisons are not known to directly interfere with DNA repair.
The ERCC2-deficient cell line, XP6BE, expresses simultaneously a truncated protein and a single nucleotide-mutated protein. This mutant protein has no helicase activity and cannot participate to DNA repair, but it is able to anchor the CAK subcomplex on the core of the TFIIH complex (17) . The CAK subcomplex displays two different functions as the substrate of CDK7 is dependent on the molecular context: when it is integrated in the TFIIH complex, it activates RNA Pol II, whereas as part of the free CAK complex, it is responsible for the activation of CDK1 (18) . When CAK is anchored in the TFIIH complex, it is not available for mitosis triggering and cells would then be less sensitive to mitotic inhibitors. At mitosis entry, reduced levels of ERCC2 allow the release of CAK, which becomes available for CDK1 activation and this sensitizes the cells to mitotic poisons; the same would be true if CAK is destabilized from TFIIH by an alteration of its constitutive proteins. This has been shown to be true for ERCC2 alterations in drosophila where downregulation of ERCC2 contributes to the upregulation of mitotic CAK activity and positively regulates mitotic progression (19) . There is, therefore, a clear role for ERCC2 in mitotic control, which has been recently confirmed by Li et al. (20) who showed the intervention of ERCC2 in mitotic kinase activity, spindle dynamics and chromosome segregation through regulation of CDK7 localization.
In order to study this second hypothesis, we knocked down the expression of ERCC2 in XP6BE cells, using the now classical approach of siRNA. We were able to significantly decrease ERCC2 protein expression by 60-100% according to the experiment and study in these conditions cell cycle distribution, CDK1 activity as well as the cisplatin and paclitaxel cytotoxicities in ERCC2-knocked down cells as compared with control XP6BE cells. A block in G 2 /M cell cycle phase as well as an increase in CDK1-mediated histone H1 phosphorylation was observed in ERCC2-knocked down cells. Cell sensitivity to cisplatin was not modified but sensitivity to paclitaxel was significantly increased by 3-to 5-fold. This result shows that the absence of catalytic activity does not hinder ERCC2 from participating in the regulation of mitosis entry. This is in favor of a role of the mutant ERCC2 peptide chain on CAK stabilization despite the loss of its catalytic activity.
We showed in addition that the decrease in ERCC2 mRNA expression associated with the ERCC2 Lys751Gln polymorphism could be attributed to the decrease in mRNA stability, this phenomenon being likely due to the profound rearrangement of its secondary structure. Such a change in mRNA stability is a cause of single-nucleotide polymorphism-associated variations in gene expression (21) . ERCC2 gene polymorphism and paclitaxel sensitivity It can be concluded from this work that the increased sensitivity of ERCC2 variant cell lines to spindle poisons is a consequence of the lower expression of ERCC2, which is likely due to a decrease in stability of the variant ERCC2 mRNA.
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